Log in with your email address username.


[Correspondence] Low-dose hydrocortisone in extremely preterm infants

The study by Olivier Baud and colleagues1 provides additional insight into the use of hydrocortisone in the prevention of bronchopulmonary dysplasia in premature infants. The large, multicentre, double-blind randomised controlled trial showed that, in extremely preterm infants born before 28 weeks, the rate of survival without bronchopulmonary dysplasia (defined as a requirement for respiratory support and oxygen requirement at 36 weeks of postmenstrual age) was significantly increased by prophylactic low-dose hydrocortisone given in the first 10 days of life.